Compare PCRX & DAKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | DAKT |
|---|---|---|
| Founded | 2006 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Office Equipment/Supplies/Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2010 | 1996 |
| Metric | PCRX | DAKT |
|---|---|---|
| Price | $23.78 | $19.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $30.25 | N/A |
| AVG Volume (30 Days) | ★ 518.7K | 409.2K |
| Earning Date | 05-07-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | 0.16 | ★ 0.75 |
| Revenue | $541,533,000.00 | ★ $608,932,000.00 |
| Revenue This Year | $6.78 | $12.94 |
| Revenue Next Year | $8.54 | $8.32 |
| P/E Ratio | $150.19 | ★ $26.49 |
| Revenue Growth | ★ 26.04 | 6.89 |
| 52 Week Low | $18.80 | $11.97 |
| 52 Week High | $27.99 | $28.27 |
| Indicator | PCRX | DAKT |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 37.72 |
| Support Level | $23.74 | $18.64 |
| Resistance Level | $23.94 | $19.38 |
| Average True Range (ATR) | 0.73 | 0.75 |
| MACD | 0.11 | 0.12 |
| Stochastic Oscillator | 75.36 | 8.64 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.